SCARB2 and Parkinson disease: LIMP-2 loss-of-function mutations result in reduced lysosomal GCase activity with consequent accumulation of the GCase substrate glucosylceramide, glucosylsphingosine and the fibril-forming protein α-synuclein, characteristic pathological markers of Gaucher disease and Parkinson’s disease, respectively11.